A significant leap in the realm of healthcare innovation has been announced as Ultromics, a pioneering force in AI diagnostics for cardiovascular care, successfully secured $55 million in Series C financing. This substantial Series C funding round, co-led by major investors like L&G, Allegis Capital, and Lightrock, signals a pivotal moment for scaling nationwide efforts to combat the pervasive challenge of undiagnosed heart failure at an unprecedented scale, leveraging advanced medical technology.
Globally, heart failure remains a critical and costly health crisis, with a staggering number of cases still going undetected, leading to delayed treatment and increased healthcare expenditures. Traditional diagnostic methods often fall short, resulting in a dangerous blind spot where patients might not receive timely intervention. Ultromics directly addresses this by harnessing artificial intelligence to enhance the accuracy and efficiency of early detection.
Central to Ultromics’ innovative approach is the FDA-cleared and Medicare-reimbursed EchoGo® platform. This state-of-the-art cardiology solution utilizes AI diagnostics to extract subtle, often hidden, disease signals from routine echocardiograms. It specifically targets elusive forms of heart failure, such as HFpEF and cardiac amyloidosis, enabling clinicians to identify high-risk patients earlier without the need for new, disruptive hardware or complex changes to existing clinical workflows.
The efficacy of the EchoGo® platform is underscored by its extensive validation. Built on years of rigorous clinical study and trained on one of the world’s largest real-world echo datasets, Ultromics’ technology has been proven across 25 peer-reviewed studies. Notably, clinical trials have shown EchoGo® improved the detection of HFpEF by an impressive 73.6% compared to standard clinical risk scores, demonstrating its profound impact on diagnostic precision.
Leaders in the investment community have lauded Ultromics’ potential. Dr. Ross Upton, CEO and Founder, emphasized how the platform empowers clinicians to utilize existing data more effectively to identify disease progression. Investors from L&G, Lightrock, and Allegis Capital highlighted the massive market opportunity for this cutting-edge medical technology to transform cardiovascular disease detection and treatment, affirming their belief in Ultromics’ mission and scalable solution.
With this new infusion of capital, Ultromics is poised for significant expansion across the U.S. The company is actively building regional clusters of clinical and commercial traction, partnering with flagship institutions like Duke Health and Mayo Clinic. This strategic scaling aims to make AI diagnostics a default component of routine cardiac care, reaching high-prevalence regions and extending the reach of advanced cardiology solutions.
Recent advancements further solidify Ultromics’ leadership in the field. The company received FDA Breakthrough Device clearance for EchoGo® Amyloidosis in late 2024 and launched EchoGo® Score in 2025, which adds AI-driven probability scoring to enhance HFpEF detection. These clinical breakthroughs, coupled with Medicare reimbursement for both outpatient and inpatient use, provide a robust foundation for widespread adoption of this vital healthcare innovation.
Emerging from a collaborative foundation with the University of Oxford, NHS, and Mayo Clinic, Ultromics is redefining the landscape of cardiovascular care. By making sophisticated AI diagnostics accessible through standard ultrasound scans, the company is on a mission to close one of medicine’s most dangerous diagnostic gaps, ensuring millions of patients receive timely and accurate diagnoses for heart failure, ultimately saving lives and reducing healthcare costs.
Leave a Reply